Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 13, 2022 at 04:32 pm EDT
Share
Chunghwa Chemical Synthesis & Biotech Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was TWD 529.53 million compared to TWD 421.61 million a year ago. Net income was TWD 127.66 million compared to TWD 98.25 million a year ago. Basic earnings per share from continuing operations was TWD 1.65 compared to TWD 1.27 a year ago. Diluted earnings per share from continuing operations was TWD 1.63 compared to TWD 1.26 a year ago. Basic earnings per share was TWD 1.65 compared to TWD 1.27 a year ago. Diluted earnings per share was TWD 1.63 compared to TWD 1.26 a year ago.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.